The PTAB continues to play a pivotal role in shaping the intellectual property landscape, with several important developments in 2024—from new USPTO rulemaking to significant Director Review decisions.

In part one, we focused on key case highlights and important statistics from the past year. In part two, PTAB Year in Review: Life Sciences, Eldora Ellison, Olga Partington, and Trey Powers addressed PTAB developments that directly impact the biotechnology and pharmaceutical sectors, including:

  • Leveraging experimental data in proceedings;
  • Written description and enablement of genus claims;
  • Relying on inherent properties; and
  • Challenging and defending chemical claims.

Note: CLE will not be available for On Demand viewers.

Related Professionals

Related Industries

Related Services